Biogen Inc. (BIIB)
Biological Products, (No Diagnostic Substances) · market cap $33.1B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-12-01 (est.)Phase 3 · Felzartamabimp 9/10
- 2026-12-31 (est.)Phase 3 · Lecanemab SCimp 9/10
- 2027-01-15 (est.)Phase 2 · Tofersenimp 7/10
- 2027-03-15 (est.)Phase 3 · anti-TNF therapyimp 9/10
- 2027-05-20 (est.)Phase 3 · BIIB017 (peginterferon beta-1a)imp 9/10
- 2027-05-31 (est.)Phase 3 · Felzartamabimp 9/10
- 2027-06-25 (est.)Phase 2 · APL-3007, pegcetacoplan (APL-2)imp 7/10
- 2027-07-15 (est.)Phase 3 · Pegcetacoplanimp 9/10
| Asset | Phase | Indication |
|---|---|---|
| Leqembi | Approved | Alzheimer Disease |
| BIIB080 | Phase 2 | Alzheimer Disease |
| Tofersen | Approved | ALS (SOD1) |
| APL2 | Phase 3 | FSGS |
| APL-3007, pegcetacoplan (APL-2) | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration |
| Lecanemab SC | Phase 3 | Early Alzheimer's Disease |
| Antiparkinsonian Agent(s) | Phase 2 | Parkinson Disease |
| Lecanemab IV | Phase 3 | Early Alzheimer's Disease |
| Pegcetacoplan | Phase 3 | C3G |
| Baminercept alfa 3 | Phase 2 | Rheumatoid Arthritis |
| Baminercept alfa 4 | Phase 2 | Rheumatoid Arthritis |
| Baminercept alfa 2 | Phase 2 | Rheumatoid Arthritis |
| Baminercept alfa 5 | Phase 2 | Rheumatoid Arthritis |
| CVP | Phase 2 | Non-Hodgkins Lymphoma |
| Dextromethorphan | Phase 3 | Relapsing-Remitting Multiple Sclerosis |
| SAGE 217 | Phase 3 | Postpartum Depression |
| Ibritumomab Tiuxetan | Phase 2 | Non-Hodgkins Lymphoma |
| BIIB019 (Daclizumab) | Phase 3 | Relapsing-Remitting Multiple Sclerosis |
| meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) | Phase 2 | Relapsing Forms of Multiple Sclerosis |
| S-warfarin | Phase 3 | Relapsing-Remitting Multiple Sclerosis |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for BIIB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
